메뉴 건너뛰기




Volumn 175, Issue 12, 2006, Pages 1545-1552

Recognition and management of neuropsychiatric complications in Parkinson's disease

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CITALOPRAM; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; LORAZEPAM; METHYLPHENIDATE; MIRTAZAPINE; NORTRIPTYLINE; OLANZAPINE; OXAZEPAM; PAROXETINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

EID: 33845641331     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060542     Document Type: Review
Times cited : (60)

References (60)
  • 1
    • 0037418066 scopus 로고    scopus 로고
    • Current concepts in the diagnosis and management of Parkinson's disease
    • Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 2003;168(3):293-301.
    • (2003) CMAJ , vol.168 , Issue.3 , pp. 293-301
    • Guttman, M.1    Kish, S.J.2    Furukawa, Y.3
  • 2
    • 0032837272 scopus 로고    scopus 로고
    • Range of neuropsychiatric disturbances in patients with Parkinson's disease
    • Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-6.
    • (1999) J Neurol Neurosurg Psychiatry , vol.67 , pp. 492-496
    • Aarsland, D.1    Larsen, J.P.2    Lim, N.G.3
  • 3
    • 33646107153 scopus 로고    scopus 로고
    • Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. J Neurology 2006;66:996-1002.
    • (2006) J Neurology , vol.66 , pp. 996-1002
    • Miyasaki, J.M.1    Shannon, K.2    Voon, V.3
  • 5
    • 0023753297 scopus 로고
    • Evidence for atypical depression in Parkinson's disease
    • Schiffer RB, Kurlan R, Rubin A, et al. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988;145:1020-2.
    • (1988) Am J Psychiatry , vol.145 , pp. 1020-1022
    • Schiffer, R.B.1    Kurlan, R.2    Rubin, A.3
  • 6
    • 33645151619 scopus 로고    scopus 로고
    • Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke
    • Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005;70(Suppl 1):148-52.
    • (2005) J Neurol Neurosurg Psychiatry , vol.70 , Issue.SUPPL. 1 , pp. 148-152
    • Rickards, H.1
  • 7
    • 0033693186 scopus 로고    scopus 로고
    • The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease
    • Leentjens AF, Verhey FR, Liujckx GJ, et al. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000;15:1221-4.
    • (2000) Mov Disord , vol.15 , pp. 1221-1224
    • Leentjens, A.F.1    Verhey, F.R.2    Liujckx, G.J.3
  • 8
    • 0033853816 scopus 로고    scopus 로고
    • The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease
    • Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Pdychiatry 2000;15:644-9.
    • (2000) Int J Geriatr Pdychiatry , vol.15 , pp. 644-649
    • Leentjens, A.F.1    Verhey, F.R.2    Lousberg, R.3
  • 9
    • 17744384689 scopus 로고    scopus 로고
    • Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease
    • Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001;6:350-2.
    • (2001) Mol Psychiatry , vol.6 , pp. 350-352
    • Mossner, R.1    Henneberg, A.2    Schmitt, A.3
  • 10
    • 0028822713 scopus 로고
    • Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study
    • Maricle RA, Nutt JG, Valentine RJ, et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:1757-60.
    • (1995) Neurology , vol.45 , pp. 1757-1760
    • Maricle, R.A.1    Nutt, J.G.2    Valentine, R.J.3
  • 11
    • 22144452936 scopus 로고    scopus 로고
    • The feasibility of using cognitive behaviour therapy for depression associated with Parkinson's disease: A literature review
    • Cole K, Vaughan FL. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson's disease: a literature review. Parkinsonism Relat Disord 2005;11:260-76.
    • (2005) Parkinsonism Relat Disord , vol.11 , pp. 260-276
    • Cole, K.1    Vaughan, F.L.2
  • 12
    • 27744564717 scopus 로고    scopus 로고
    • Antidepressant studies in Parkinson's disease: A review and meta-analysis
    • Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-9.
    • (2005) Mov Disord , vol.20 , pp. 1161-1169
    • Weintraub, D.1    Morales, K.H.2    Moberg, P.J.3
  • 13
    • 0032949690 scopus 로고    scopus 로고
    • Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series
    • Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord 1999;14:155-7.
    • (1999) Mov Disord , vol.14 , pp. 155-157
    • Richard, I.H.1    Maughn, A.2    Kurlan, R.3
  • 14
    • 0032942169 scopus 로고    scopus 로고
    • Management of Parkinson's disease: A review of current and new therapies
    • Mendis T, Suchowersky O, Lang A, et al. Management of Parkinson's disease: a review of current and new therapies. Can J Neurol Sci 1999;26:89-103.
    • (1999) Can J Neurol Sci , vol.26 , pp. 89-103
    • Mendis, T.1    Suchowersky, O.2    Lang, A.3
  • 15
    • 0030987172 scopus 로고    scopus 로고
    • Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
    • Parkinson Study Group
    • Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997;48:1070-7.
    • (1997) Neurology , vol.48 , pp. 1070-1077
    • Richard, I.H.1    Kurlan, R.2    Tanner, C.3
  • 17
    • 28144444507 scopus 로고    scopus 로고
    • Non-invasive brain stimulation for Parkinson's disease: A systematic review and meta-analysis of the literature
    • Fregni F, Simon DK, Wu A, et al. Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 2005;76:1614-23.
    • (2005) J Neurol Neurosurg Psychiatry , vol.76 , pp. 1614-1623
    • Fregni, F.1    Simon, D.K.2    Wu, A.3
  • 19
    • 0036754180 scopus 로고    scopus 로고
    • Methylphenidate treats apathy in Parkinson's disease
    • Chatrerjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:461-2.
    • (2002) J Neuropsychiatry Clin Neurosci , vol.14 , pp. 461-462
    • Chatrerjee, A.1    Fahn, S.2
  • 21
    • 0038084268 scopus 로고    scopus 로고
    • Prospective study of phobic anxiety and risk of Parkinson's disease
    • Weisskopf MG, Chen H, Schwarzschild MA, et al. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 2003;18:646-51.
    • (2003) Mov Disord , vol.18 , pp. 646-651
    • Weisskopf, M.G.1    Chen, H.2    Schwarzschild, M.A.3
  • 22
    • 0022893596 scopus 로고
    • Buspirone, Parkinson's disease, and the locus ceruleus
    • Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 1986;9:373-8.
    • (1986) Clin Neuropharmacol , vol.9 , pp. 373-378
    • Ludwig, C.L.1    Weinberger, D.R.2    Bruno, G.3
  • 23
    • 11244349103 scopus 로고    scopus 로고
    • The ups and downs of Parkinson disease: A prospective study of mood and anxiety fluctuations
    • Richard IH, Franks, McDermott MP, et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 2004;17:201-7.
    • (2004) Cogn Behav Neurol , vol.17 , pp. 201-207
    • Richard, I.H.1    Franks2    McDermott, M.P.3
  • 24
    • 22144475386 scopus 로고    scopus 로고
    • Psychotic symptoms in Parkinson's disease. From description to etiology
    • Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005;252:753-64.
    • (2005) J Neurol , vol.252 , pp. 753-764
    • Papapetropoulos, S.1    Mash, D.C.2
  • 25
    • 0342424352 scopus 로고    scopus 로고
    • Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
    • Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45.
    • (2000) Brain , vol.123 , pp. 733-745
    • Fenelon, G.1    Mahieux, F.2    Huon, R.3
  • 26
    • 0034983839 scopus 로고    scopus 로고
    • Prospective study of hallucinations and delusions in Parkinson's disease
    • Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-8.
    • (2001) J Neurol Neurosurg Psychiatry , vol.70 , pp. 734-738
    • Holroyd, S.1    Currie, L.2    Wooten, G.F.3
  • 28
    • 0034973443 scopus 로고    scopus 로고
    • An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
    • Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56 (Suppl 5):S1-S88.
    • (2001) Neurology , vol.56 , Issue.SUPPL. 5
    • Olanow, C.W.1    Watts, R.L.2    Koller, W.C.3
  • 29
    • 19544378167 scopus 로고    scopus 로고
    • Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias
    • Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-7.
    • (2005) J Clin Psychiatry , vol.66 , pp. 633-637
    • Aarsland, D.1    Perry, R.2    Larsen, J.P.3
  • 30
    • 0038485957 scopus 로고    scopus 로고
    • Long-term outcome of quetiapine use for psychosis among Parkinsonian patients
    • Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Discord 2003;18:510-4.
    • (2003) Mov Discord , vol.18 , pp. 510-514
    • Fernandez, H.H.1    Trieschmann, M.E.2    Burke, M.A.3
  • 31
    • 2342443881 scopus 로고    scopus 로고
    • Quetiapine improves psychotic symptoms and cognition in Parkinson's disease
    • Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35.
    • (2004) Mov Disord , vol.19 , pp. 29-35
    • Juncos, J.L.1    Roberts, V.J.2    Evatt, M.L.3
  • 32
    • 0034107042 scopus 로고    scopus 로고
    • Atypical antipsychotics in the treatment of drug-induced psychosis hi Parkinson's disease
    • Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis hi Parkinson's disease. Mov Disord 2000;15:201-11.
    • (2000) Mov Disord , vol.15 , pp. 201-211
    • Friedman, J.H.1    Factor, S.A.2
  • 33
    • 26444527544 scopus 로고    scopus 로고
    • Treatment of dementia with Lewy bodies and Parkinson's disease dementia
    • Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord 2005;26(Suppl 12):S77-82.
    • (2005) Mov Disord , vol.26 , Issue.SUPPL. 12
    • Poewe, W.1
  • 34
    • 1542374145 scopus 로고    scopus 로고
    • Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies
    • Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 2004;31:7-21.
    • (2004) Can J Neurol Sci , vol.31 , pp. 7-21
    • Camicioli, R.1    Fisher, N.2
  • 35
    • 33846016934 scopus 로고    scopus 로고
    • Neuropsychiatric symptoms in patients with PD and dementia: Frequency, profile and associated caregiver stress
    • [Epub ahead of print 2006 July 4]. Available: (accessed 2006 Oct 6)
    • Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with PD and dementia: Frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry [Epub ahead of print 2006 July 4]. Available: http://jnnp.bmjjournals .com/cgi/rapidpdf/jnnp.2005.083113v1.pdf (accessed 2006 Oct 6).
    • J Neurol Neurosurg Psychiatry
    • Aarsland, D.1    Bronnick, K.2    Ehrt, U.3
  • 36
    • 0016823810 scopus 로고
    • "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
    • Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
    • (1975) J Psychiatr Res , vol.12 , pp. 189-198
    • Folstein, M.F.1    Folstein, S.E.2    McHugh, P.R.3
  • 37
    • 33845678859 scopus 로고    scopus 로고
    • Guidelines for randomized clinical studies in Parkinson's disease with dementia and dementia with Lewy bodies
    • In press
    • Camicioli R, Gauthier S. Guidelines for randomized clinical studies in Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci. In press.
    • Can J Neurol Sci
    • Camicioli, R.1    Gauthier, S.2
  • 38
    • 0842325101 scopus 로고    scopus 로고
    • Randomized placebo-controlled trial ofdonepezil in cognitive impairment in Parkinson's disease
    • Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial ofdonepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8.
    • (2004) Int J Geriatr Psychiatry , vol.19 , pp. 1-8
    • Leroi, I.1    Brandt, J.2    Reich, S.G.3
  • 39
    • 0031060220 scopus 로고    scopus 로고
    • Cognitive deficits in Parkinson's disease
    • Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
    • (1997) J Neurol , vol.244 , pp. 2-8
    • Dubois, B.1    Pillon, B.2
  • 40
    • 0021328595 scopus 로고
    • Parkinson's disease: Neuron loss in the nucleus basalis without concomitant Alzheimer's disease
    • Nakano J, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-8.
    • (1984) Ann Neurol , vol.15 , pp. 415-418
    • Nakano, J.1    Hirano, A.2
  • 41
    • 33144489150 scopus 로고    scopus 로고
    • Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium [published erratum in Neurology 2005;65:1992]
    • McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium [published erratum in Neurology 2005;65:1992]. Neurology 2005;65:1863-72.
    • (2005) Neurology , vol.65 , pp. 1863-1872
    • McKeith, I.G.1    Dickson, D.W.2    Lowe, J.3
  • 42
    • 33645328813 scopus 로고    scopus 로고
    • Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: A conceptual summary
    • Feldman HH, Gauthier S, Chertkow H, et al. Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sci 2006;33:6-26.
    • (2006) Can J Neurol Sci , vol.33 , pp. 6-26
    • Feldman, H.H.1    Gauthier, S.2    Chertkow, H.3
  • 43
    • 33645520639 scopus 로고    scopus 로고
    • Cholinesterase inhibitors for Parkinson's disease dementia
    • [review]. CD004747
    • Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia [review]. Cochrane Database Syst Rev 2006;(1):CD004747.
    • (2006) Cochrane Database Syst Rev , Issue.1
    • Maidment, I.1    Fox, C.2    Boustani, M.3
  • 44
    • 10044283107 scopus 로고    scopus 로고
    • Rivastigmine for dementia associated with Parkinson's disease
    • Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
    • (2004) N Engl J Med , vol.351 , pp. 2509-2518
    • Emre, M.1    Aarsland, D.2    Albanese, A.3
  • 45
    • 0036265213 scopus 로고    scopus 로고
    • Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study
    • Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12.
    • (2002) J Neurol Neurosurg Psychiatry , vol.72 , pp. 708-712
    • Aarsland, D.1    Laake, K.2    Larsen, J.P.3
  • 46
    • 21344444811 scopus 로고    scopus 로고
    • Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study
    • Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9.
    • (2005) J Neurol Neurosurg Psychiatry , vol.76 , pp. 934-939
    • Ravina, B.1    Putt, M.2    Siderowf, A.3
  • 47
    • 0142091310 scopus 로고    scopus 로고
    • Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
    • Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18:937-41.
    • (2003) Int J Geriatr Psychiatry , vol.18 , pp. 937-941
    • Aarsland, D.1    Hutchinson, M.2    Larsen, J.P.3
  • 48
    • 21044442252 scopus 로고    scopus 로고
    • Sleep issues in Parkinson's disease
    • Adler CH, Thorpy MJ. Sleep issues in Parkinson's disease. Neurology 2005;64 (Suppl 3):S12-20.
    • (2005) Neurology , vol.64 , Issue.SUPPL. 3
    • Adler, C.H.1    Thorpy, M.J.2
  • 49
    • 18844365394 scopus 로고    scopus 로고
    • Excessive daytime sleepiness in parkinsonism
    • Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9: 185-200.
    • (2005) Sleep Med Rev , vol.9 , pp. 185-200
    • Arnulf, I.1
  • 50
    • 33645836498 scopus 로고    scopus 로고
    • Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder
    • Postuma RB, Lang AE, Massicotte-Marquez J, et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006;66:845-51.
    • (2006) Neurology , vol.66 , pp. 845-851
    • Postuma, R.B.1    Lang, A.E.2    Massicotte-Marquez, J.3
  • 51
    • 0141738376 scopus 로고    scopus 로고
    • Compulsive use of dopamine replacement therapy in Parkinson's disease Reward systems gone awry?
    • Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease Reward systems gone awry? Laacet Neurol 2003;2:595-604.
    • (2003) Laacet Neurol , vol.2 , pp. 595-604
    • Lawrence, A.D.1    Evans, A.H.2    Lees, A.J.3
  • 52
    • 24944552052 scopus 로고    scopus 로고
    • Pathological gambling in Parkinson's disease
    • Stocchi F. Pathological gambling in Parkinson's disease. Lancet Neurol 2005;4:590-2.
    • (2005) Lancet Neurol , vol.4 , pp. 590-592
    • Stocchi, F.1
  • 53
    • 32944480345 scopus 로고    scopus 로고
    • Impulse control disorders and dopaminergic drugs
    • letter
    • Morgan JC, Iyer SS, Sethi KD. Impulse control disorders and dopaminergic drugs [letter]. Arch Neurol 2006;63:298-9.
    • (2006) Arch Neurol , vol.63 , pp. 298-299
    • Morgan, J.C.1    Iyer, S.S.2    Sethi, K.D.3
  • 55
    • 23844441981 scopus 로고    scopus 로고
    • Pathological gambling caused by drugs used to treat Parkinson disease
    • Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-81.
    • (2005) Arch Neurol , vol.62 , pp. 1377-1381
    • Dodd, M.L.1    Klos, K.J.2    Bower, J.H.3
  • 56
    • 0014693180 scopus 로고
    • L-dopa therapy in Parkinson's disease: A critical review of nine years' experience
    • Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. CMAJ 1969;101:59-68.
    • (1969) CMAJ , vol.101 , pp. 59-68
    • Barbeau, A.1
  • 57
    • 0031922957 scopus 로고    scopus 로고
    • Clozapine for dopaminergic-induced paraphilias in Parkinson's disease
    • Fernandez HH, Durso R. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord 1998;13:597-8.
    • (1998) Mov Disord , vol.13 , pp. 597-598
    • Fernandez, H.H.1    Durso, R.2
  • 58
    • 0036338706 scopus 로고    scopus 로고
    • Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline
    • Riley DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol 2002;25:234-7.
    • (2002) Clin Neuropharmacol , vol.25 , pp. 234-237
    • Riley, D.E.1
  • 59
    • 24944446759 scopus 로고    scopus 로고
    • Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy
    • Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Discord 2005;11:381-6.
    • (2005) Parkinsonism Relat Discord , vol.11 , pp. 381-386
    • Klos, K.J.1    Bower, J.H.2    Josephs, K.A.3
  • 60
    • 0025816459 scopus 로고
    • Behavioral complications of drug treatment of Parkinson's disease
    • Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-16.
    • (1991) J Am Geriatr Soc , vol.39 , pp. 708-716
    • Cummings, J.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.